Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Hoth Therapeutics Inc's Business Segments
Hoth Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Biopharmaceutical Segment
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Biopharmaceutical Segment0%
- AI Infrastructure and Technologies Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Biopharmaceutical Segment | - | - |
| AI Infrastructure and Technologies Segment | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Biopharmaceutical Segment0%
- AI Infrastructure and Technologies Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Biopharmaceutical Segment | - | - |
| AI Infrastructure and Technologies Segment | - | - |
Description of Hoth Therapeutics Inc
Hoth Therapeutics Inc is a biopharmaceutical company focused on the development of novel therapies for dermatological conditions. The company's name, Hoth, is inspired by the icy planet Hoth from the Star Wars franchise.
Founded in 2017 and based in New York City, Hoth Therapeutics is dedicated to addressing significant unmet medical needs in the dermatology space. The company leverages advanced technologies and collaborations with leading academic institutions and research organizations to develop innovative treatments.
Hoth Therapeutics has a diverse pipeline of potential therapies targeting various skin diseases, including psoriasis, atopic dermatitis, acne, and alopecia (hair loss). Psoriasis is a chronic autoimmune skin condition characterized by red, itchy, scaly patches, and atopic dermatitis refers to a condition causing inflamed, itchy, cracked skin. Acne is a common skin condition resulting from the clogging of hair follicles with oil and dead skin cells, whereas alopecia involves partial or complete hair loss.
The company's flagship candidate is BioLexa, a topical cream being developed to treat skin disorders like psoriasis and atopic dermatitis. BioLexa is designed to deliver targeted therapies directly to affected areas of the skin. It incorporates proprietary technologies, including proprietary peptides and thermal-cooling technology, to enhance drug delivery and efficacy.
Hoth Therapeutics has also formed strategic partnerships with renowned medical institutions and research organizations to advance its pipeline. Notably, the company has collaborated with the George Washington University to develop a novel therapeutic platform called HT-002, targeting atopic dermatitis. This partnership aims to develop a unique formulation to suppress inflammation associated with the condition.
Furthermore, Hoth Therapeutics is actively exploring the potential of using retinoic acid-inducible gene I (RIG-I) agonists as a novel treatment approach for skin diseases. RIG-I is an intracellular immune receptor that recognizes viral RNA and triggers immune responses. By targeting RIG-I, Hoth aims to develop a broad-spectrum antiviral therapy for common skin infections, including those caused by the herpes simplex virus-1 (HSV-1).
In addition to its dermatology-focused pipeline, Hoth Therapeutics is engaged in developing proprietary peptide therapeutics with potential applications in various diseases, such as diabetes and cancer.
Overall, Hoth Therapeutics Inc is a biopharmaceutical company at the forefront of innovative research and development in the field of dermatology. With a robust pipeline, strategic partnerships, and cutting-edge technologies, the company aims to provide novel and effective therapies for dermatological conditions, ultimately improving patients' quality of life.
Founded in 2017 and based in New York City, Hoth Therapeutics is dedicated to addressing significant unmet medical needs in the dermatology space. The company leverages advanced technologies and collaborations with leading academic institutions and research organizations to develop innovative treatments.
Hoth Therapeutics has a diverse pipeline of potential therapies targeting various skin diseases, including psoriasis, atopic dermatitis, acne, and alopecia (hair loss). Psoriasis is a chronic autoimmune skin condition characterized by red, itchy, scaly patches, and atopic dermatitis refers to a condition causing inflamed, itchy, cracked skin. Acne is a common skin condition resulting from the clogging of hair follicles with oil and dead skin cells, whereas alopecia involves partial or complete hair loss.
The company's flagship candidate is BioLexa, a topical cream being developed to treat skin disorders like psoriasis and atopic dermatitis. BioLexa is designed to deliver targeted therapies directly to affected areas of the skin. It incorporates proprietary technologies, including proprietary peptides and thermal-cooling technology, to enhance drug delivery and efficacy.
Hoth Therapeutics has also formed strategic partnerships with renowned medical institutions and research organizations to advance its pipeline. Notably, the company has collaborated with the George Washington University to develop a novel therapeutic platform called HT-002, targeting atopic dermatitis. This partnership aims to develop a unique formulation to suppress inflammation associated with the condition.
Furthermore, Hoth Therapeutics is actively exploring the potential of using retinoic acid-inducible gene I (RIG-I) agonists as a novel treatment approach for skin diseases. RIG-I is an intracellular immune receptor that recognizes viral RNA and triggers immune responses. By targeting RIG-I, Hoth aims to develop a broad-spectrum antiviral therapy for common skin infections, including those caused by the herpes simplex virus-1 (HSV-1).
In addition to its dermatology-focused pipeline, Hoth Therapeutics is engaged in developing proprietary peptide therapeutics with potential applications in various diseases, such as diabetes and cancer.
Overall, Hoth Therapeutics Inc is a biopharmaceutical company at the forefront of innovative research and development in the field of dermatology. With a robust pipeline, strategic partnerships, and cutting-edge technologies, the company aims to provide novel and effective therapies for dermatological conditions, ultimately improving patients' quality of life.
Hoth Therapeutics Inc. is a biopharmaceutical company focused on developing innovative solutions for unmet medical needs in various therapeutic areas. The company operates in specific segments, each catering to different aspects of healthcare and therapeutic innovations. Below, I outline the segments, products, and services that Hoth Therapeutics Inc. is known to offer.
Segments
1. Dermatology:
- Hoth Therapeutics has a strong focus on dermatological conditions, developing therapies for skin ailments and disorders. This segment is driven by the increasing prevalence of skin diseases and the need for effective treatments.
2. Neurology:
- The company is involved in creating treatments aimed at neurological conditions. This segment addresses the critical need for new therapeutics in disorders affecting the nervous system, including neurodegeneration and neuropathic pain.
3. Oncology:
- Hoth Therapeutics is working on developing therapies targeting various cancer forms. The oncology segment focuses on leveraging innovative approaches to treat malignancies, supporting the ongoing quest for effective cancer therapies.
Products
1. HT-001:
- HT-001 is a preclinical-stage product under development for dermatological conditions, particularly targeting conditions like atopic dermatitis. The formulation is designed to provide a novel approach to treatment, focusing on reducing inflammation and itch.
2. HT-002:
- This candidate is being developed for other dermatological applications, aiming to address skin diseases through a unique mode of action that differentiates it from existing therapies in the market.
3. HT-003:
- Targeted at neuropathic pain, HT-003 aims to offer patients an advanced therapeutic option for managing chronic pain associated with nerve damage. The product is positioned as a potential alternative to traditional pain management therapies.
4. HT-004:
- This product is in the pipeline for oncology applications, focusing on a specific cancer type. Its development reflects a commitment to addressing critical gaps in cancer treatment and providing innovative solutions for patients.
Services
1. Research and Development (R&D):
- Hoth Therapeutics invests heavily in R&D as a core service, conducting preclinical and clinical trials to explore the efficacy and safety of their therapeutics. This ongoing research helps in refining drug formulations and determining suitable patient populations.
2. Collaborative Partnerships:
- The company engages in strategic collaborations with academic institutions, biotechnology firms, and other stakeholders to harness cutting-edge research and technology. These partnerships are critical in advancing their product development pipeline and enhancing their scientific capabilities.
3. Regulatory Support:
- Hoth Therapeutics provides extensive regulatory support during the development process, navigating the complexities of FDA guidelines and ensuring compliance with regulatory requirements for clinical trials and eventual commercialization of their products.
4. Market Access and Commercialization Strategies:
- As products move closer to commercialization, Hoth Therapeutics develops strategies for market access, leveraging insights into healthcare systems and reimbursement pathways to maximize the potential reach of their therapies.
In summary, Hoth Therapeutics Inc. is actively developing a range of innovative products and services primarily focused on dermatology, neurology, and oncology. Their offerings include a selection of therapeutic candidates aimed at addressing significant unmet medical needs across various patient populations, supported by robust research and strategic partnerships in the biopharmaceutical landscape.
Segments
1. Dermatology:
- Hoth Therapeutics has a strong focus on dermatological conditions, developing therapies for skin ailments and disorders. This segment is driven by the increasing prevalence of skin diseases and the need for effective treatments.
2. Neurology:
- The company is involved in creating treatments aimed at neurological conditions. This segment addresses the critical need for new therapeutics in disorders affecting the nervous system, including neurodegeneration and neuropathic pain.
3. Oncology:
- Hoth Therapeutics is working on developing therapies targeting various cancer forms. The oncology segment focuses on leveraging innovative approaches to treat malignancies, supporting the ongoing quest for effective cancer therapies.
Products
1. HT-001:
- HT-001 is a preclinical-stage product under development for dermatological conditions, particularly targeting conditions like atopic dermatitis. The formulation is designed to provide a novel approach to treatment, focusing on reducing inflammation and itch.
2. HT-002:
- This candidate is being developed for other dermatological applications, aiming to address skin diseases through a unique mode of action that differentiates it from existing therapies in the market.
3. HT-003:
- Targeted at neuropathic pain, HT-003 aims to offer patients an advanced therapeutic option for managing chronic pain associated with nerve damage. The product is positioned as a potential alternative to traditional pain management therapies.
4. HT-004:
- This product is in the pipeline for oncology applications, focusing on a specific cancer type. Its development reflects a commitment to addressing critical gaps in cancer treatment and providing innovative solutions for patients.
Services
1. Research and Development (R&D):
- Hoth Therapeutics invests heavily in R&D as a core service, conducting preclinical and clinical trials to explore the efficacy and safety of their therapeutics. This ongoing research helps in refining drug formulations and determining suitable patient populations.
2. Collaborative Partnerships:
- The company engages in strategic collaborations with academic institutions, biotechnology firms, and other stakeholders to harness cutting-edge research and technology. These partnerships are critical in advancing their product development pipeline and enhancing their scientific capabilities.
3. Regulatory Support:
- Hoth Therapeutics provides extensive regulatory support during the development process, navigating the complexities of FDA guidelines and ensuring compliance with regulatory requirements for clinical trials and eventual commercialization of their products.
4. Market Access and Commercialization Strategies:
- As products move closer to commercialization, Hoth Therapeutics develops strategies for market access, leveraging insights into healthcare systems and reimbursement pathways to maximize the potential reach of their therapies.
In summary, Hoth Therapeutics Inc. is actively developing a range of innovative products and services primarily focused on dermatology, neurology, and oncology. Their offerings include a selection of therapeutic candidates aimed at addressing significant unmet medical needs across various patient populations, supported by robust research and strategic partnerships in the biopharmaceutical landscape.